BIVIWの企業概要
日中の時刻はETです。市場データは遅延する場合があります。
企業プロフィール
会社ウェブサイトBioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
- 業界
- Biotechnology
- セクター
- Healthcare
- 本社
- US
- 最高経営責任者（CEO）
- Cuong Viet Do
- 上場以来
- 2026年7月17日
- 従業員
- 13
市場での位置
日中レンジ
現在 $0.26
52週レンジ
現在 $0.26
- 始値
- $0.23
- 前日終値
- $0.25
- 出来高
- 634
- 0.01× 平均
- 平均出来高
- 7.68万
- 1日平均出来高
- 時価総額
- 221.81万 USD
- ベータ
- 0.3
- 市場参照 1
- 50日平均
- $0.3092
- 平均以下（-15.90%）
- 200日平均
- $0.3092
- 平均以下（-15.90%）
